Kyle Kline
Insider
First SEC filing: Aug. 27, 2025 · Latest: Aug. 27, 2025
Insider at
Insider transactions
0 buys (P)
2 sells (S)
Net: $-2,032,133
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 21, 2026 | GMED | A | 30,000 | · | · | 30,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 8, 2026 | GMED | M | 3,594 | $51.87 | $186,421 | 3,594 Direct | · | Acquired | 45.7% (price as of 2026-10-02) |
| Jan. 8, 2026 | GMED | S 10b5-1 | 3,594 | $101.10 | $363,353 | 0 Direct | -100.00% | Disposed | -25.2% (price as of 2026-10-02) |
| Jan. 8, 2026 | GMED | M | 3,594 | · | · | 3,906 Direct | -47.92% | Disposed | (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | M | 4,896 | · | · | 104 Direct | -97.92% | Disposed | (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | M | 5,000 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | M | 5,000 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | M | 5,000 | · | · | 10,000 Direct | -33.33% | Disposed | (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | M | 3,646 | · | · | 1,354 Direct | -72.92% | Disposed | (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | S 10b5-1 | 18,542 | $90.00 | $1,668,780 | 0 Direct | -100.00% | Disposed | -16.0% (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | M | 4,896 | $63.68 | $311,777 | 18,542 Direct | +35.88% | Acquired | 18.7% (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | M | 5,000 | $64.44 | $322,200 | 13,646 Direct | +57.83% | Acquired | 17.3% (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | M | 5,000 | $56.43 | $282,150 | 8,646 Direct | +137.14% | Acquired | 34.0% (price as of 2026-10-02) |
| Dec. 1, 2025 | GMED | M | 3,646 | $53.14 | $193,748 | 3,646 Direct | · | Acquired | 42.3% (price as of 2026-10-02) |
| July 18, 2025 | GMED | A | 20,909 | · | · | 20,909 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 21, 2026 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock | $94.15 | Jan. 21, 2036 | 30,000 | Acquired |
| Jan. 8, 2026 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock | $51.87 | March 14, 2034 | 3,594 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock | $63.68 | Jan. 27, 2032 | 4,896 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock | $63.68 | Jan. 27, 2032 | 5,000 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock | $64.44 | Jan. 25, 2031 | 5,000 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock | $56.43 | Feb. 27, 2034 | 5,000 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock | $53.14 | March 24, 2033 | 3,646 | Disposed |
| July 18, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock | $56.34 | July 18, 2035 | 20,909 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 7 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | 5,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | 5,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | 5,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | 5,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | 15,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | 7,500 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | 9,091 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $334,040 | $50,000 | · | · | $200,000 | · | $33,264 | $1,380,258 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.